Reevaluating NICE’s Cost-Effectiveness Thresholds: The QALY Debate

By João L. Carapinha

December 17, 2024

NICE (National Institute for Health and Clinical Excellence) recently commented on whether their cost-effectiveness thresholds should change, focusing on the intricate relationship between quality-adjusted life years (QALYs) and the incremental cost-effectiveness ratio (ICER). The ongoing debate about NICE’s cost-effectiveness thresholds reveals important concerns and insights relevant to healthcare technology assessment.

Ongoing Debate on QALYs

The use of QALYs in cost-effectiveness analysis remains a contentious issue. Critics argue that QALYs may not adequately capture the complexity of health outcomes and can be discriminatory, especially against specific patient groups. In NICE’s context, the debate centers on whether QALYs should be adjusted to reflect continuous economic growth and willingness to pay for innovation. Despite these discussions, QALYs continue to be a prevalent metric in the UK for evaluating health interventions.

Cost-Effectiveness Thresholds

Historically, NICE has employed a cost-effectiveness threshold range of £20,000 to £30,000 per QALY gained. This threshold is essential for determining whether new healthcare technologies offer good value for money. However, the NICE blog post argues that merely increasing the cost per QALY may not remedy access issues to innovative healthcare technologies. Rather, we highlight the need for the ICER to accurately reflect the country’s growing economic development and societal willingness to pay for innovation.

Economic Development and Willingness to Pay

The UK’s cost-effectiveness threshold has remained relatively static, which may signal a lag in the country’s willingness to invest in innovative healthcare technologies, compared to its international peers. It is crucial for these thresholds to adapt alongside economic shifts and changing societal values to maintain their relevance and effectiveness.

Positive Recommendations and Fixed Thresholds

Despite the ongoing debates, NICE has recommended positive outcomes for 86% of applications, demonstrating a generally supportive stance towards new technologies. The cost-effectiveness threshold is set to remain unchanged until 2028, which offers a degree of stability for healthcare providers and manufacturers.

Methodological Elements and Future Contributions

The continuous methodological discussions are significant, particularly regarding the adjustments of thresholds. Contributing to this discussion can enhance the process of determining appropriate cost-effectiveness thresholds. Factors such as uncertainty in the evidence base, disease burden, and alternative treatment availability all play vital roles in informing NICE’s decisions.

In summary, NICE explores the complex and multifaceted discussions surrounding cost-effectiveness thresholds and QALYs. We highlight the need for thresholds to be dynamic and reflective of broader economic and societal changes while also focussing on the importance of methodological rigor in these evaluations. The examination of NICE’s cost-effectiveness thresholds provides essential insights for further engagement in this crucial debate.

Reference url

Recent Posts

allopurinol Marfan syndrome orphan
       

Allopurinol Designated an Orphan Drug for Marfan Syndrome

🌟 What does the EMA’s orphan drug designation for allopurinol mean for those impacted by Marfan syndrome?

This groundbreaking move highlights a significant step forward in tackling rare diseases, offering hope to patients with limited treatment options. Allopurinol, traditionally used for gout, shows promise in addressing life-threatening aortic complications associated with Marfan syndrome, thanks to its antioxidant properties.

Dive into the implications of this development for healthcare innovation, patient access, and the future of rare disease treatment!

#SyenzaNews #HealthEconomics #Innovation #MarketAccess

marstacimab hemophilia B
                

NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment Landscapes and Economic Implications

💡 Are we witnessing a paradigm shift in hemophilia treatment?

The recent recommendation from NICE for marstacimab as a novel therapy for severe hemophilia B is a game-changer. With its ability to provide effective prophylaxis while potentially lowering treatment costs, this could reshape patient care and health economics in this space.

Dive into the implications this has for patients and healthcare providers, and why marstacimab’s approval could be a pivotal moment for hemophilia management.

Explore the full article for deeper insights!

#SyenzaNews #HealthEconomics #HealthcareInnovation #MarketAccess

HPV-related cancer trends
    

HPV-Related Cancer Trends in South Africa 2011-2021

🌍 Are we witnessing a rise in HPV-related cancer in South Africa?

A recent analysis of data from the South African National Cancer Registry highlights concerning trends: while cervical cancer rates are declining, there’s an alarming rise in non-cervical anogenital cancers. This underscores the urgent need for enhanced cancer prevention and access to efficient healthcare services in the country.

Dive into the findings and explore the implications for health systems and policies.

#SyenzaNews #HealthEconomics #HealthcareInnovation #GlobalHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.